Increasing evidence suggests that the hepatitis C virus (HCV) might be involved in the pathogenesis of B cell non-Hodgkin's lymphomas (NHL). Since several HCV genotypes are currently identifiable and might be involved in the pathogenesis of different diseases (with different severity and responsiveness to therapy), the aim of our study was to assess the prevalence of viral genotypes in a group of patients with HCV-related NHL. Among 470 consecutive patients, 42 HCV Ab-positive cases were identified. HCV RNA could be detected by reverse transcriptase-polymerase chain reaction and genotyping performed in 31 of these cases. As compared to our control group (211 healthy blood donors and patients with chronic liver disease), a striking high prevalence of genotype 2ac was detected among B cell NHL (48.4 vs 9.0%), with a relative risk of infection of 5.37 (P Ͻ 0.0001). No major differences were observed in the distribution of NHL histotypes and in the clinical features among patients with genotype 1b (the other most frequent genotype) or 2ac, a part from a trend towards a higher percentage of liver disease and a lower likelihood of response to interferon for patients with genotype 1b. The same high prevalence of genotype 2ac has been recently reported in patients with mixed cryoglobulinemia (MC), monoclonal gammopathies, B cell NHL complicating MC and autoimmune hepatitis. All these data taken together suggest that genotype 2ac might be involved in the pathogenesis of lymphoproliferative and autoimmune disorders.
Introduction
Increasing evidence suggests that the hepatitis C virus (HCV) is the causative agent of the so-called mixed cryoglobulinemia (MC) [1] [2] [3] [4] and that it might be involved in the pathogenesis of B cell non-Hodgkin's lymphomas (NHL) complicating MC 5, 6 or arising 'de novo'. 7 On the basis of its prevalence among 537 patients with different lymphoproliferative disorders, 180 with MGUS (monoclonal gammopathy of unknown significance), and 470 with B cell NHL, we previously identified the B cell NHL (in particular the immunocytoma) associated with the production of cryoglobulins (in particular type II), as the probable pathogenetic target of HCV. [8] [9] [10] [11] Since several investigators have reported on the significance of specific HCV genotypes as determinants of liver disease severity and responsiveness to interferon-␣ (IFN), [12] [13] [14] [15] [16] [17] [18] [19] one might speculate on the involvement of particular viral genotypes in the pathogenesis, clinical features and response to therapy of HCV-related B cell NHL. With this in mind we have now assessed the prevalence of viral genotypes in our group of patients with HCV-related B cell NHL.
Patients
Since January 1991, 470 unselected, consecutive patients affected by B cell NHL have been observed at the Division of Hematology of the Udine University Hospital. All patients were Italian-born and HIV-negative. The NHL were classified according to the REAL (Revised European-American Lymphoma) classification, 20 and the histologic subtypes were distributed as follows: 11 131 chronic lymphocytic leukemia; three prolymphocytic leukemia; 35 hairy cell leukemia; 70 lymphoplasmacytoid lymphoma/immunocytoma; 87 follicle center lymphoma; 47 marginal zone lymphoma; 11 mantle cell lymphoma; 77 diffuse large cell lymphoma; three Burkitt's lymphoma; two lymphoblastic lymphoma and four B cell lymphoma, unspecified.
Antibodies (Ab) against HCV were sought in all (at diagnosis in all patients seen after January 1993; during follow-up for patients diagnosed before, with none of these having received IFN as treatment), and 42 HCV-Ab-positive patients were identified. In this group of patients, HCV RNA was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) followed by genotyping of RNA-positive cases. Since eight HCV-Ab-positive patients (two chronic lymphocytic leukemia, three marginal zone lymphoma and three follicle center lymphoma) tested negative for HCV RNA, and in other three patients (one chronic lymphocytic leukemia and two immunocytoma) the lack of stocked serum and the patients' death anteceded our analysis preventing us from performing this test, HCV RNA was detected and genotyping performed in 31 patients. The control group included 211 unselected HCV RNA-positive subjects (91 healthy blood donors and 120 patients with chronic liver disease) that were consecutively genotyped in our laboratory.
Methods
At diagnosis hematological parameters, routine blood chemistry and urianalysis were carried out in all patients by standard methods. Cryoglobulin isolation was performed as described elsewhere. 8 Rheumatoid factor (RF) was measured in HCVpositive patients by rate nephelometry. Liver and kidney biopsies were obtained in patients with clinical and biochemical signs of chronic liver or renal disease, as clinically indicated.
Serological tests
Screening for anti-HCV antibody was carried out with a second-generation enzyme immunoadsorbent assay (EIA II) (Ortho Diagnostic System, Raritan, NJ, USA); positive samples were retested in duplicate and confirmed by a second-generation recombinant immunoblot assay (RIBA II) (Ortho), according to the manufacturer's instructions.
Detection of HCV RNA and genotyping HCV RNA was detected by a commercially available PCR assay (Amplicor HCV PCR Kit; Roche Molecular System, Basel, Switzerland) based on combined reverse transcription (RT)-PCR assay and subsequent non-isotopic hybridization of amplified products. 21 Genotyping was performed using two different methods. The first 8 is based on the amplification of cDNA using two sets of primers specific for the 5′UTR and for the E region of HCV genome and subsequent Southern blot hybridization, using four 32 P-labeled genotype-specific oligonucleotide probes. 22 This assay allows the identification of four genotypes, respectively, 1a, 1b, 2, 3, according to Simmonds classification 23 but is very laborious and does not allow the identification of some clinically relevant types and subtypes. Due to these limitations a second assay (2nd generation Line Probe Assay, LiPA; Innogenetics, Brussels, Belgium) was recently adopted. This test is based on the amplification, using universal biotinylated primers, of the 5′UTR of HCV genome followed by hybridization of PCR product of genotype-specific immobilized probes. This assay allows the discrimination among six HCV genotypes (1-6) and their more relevant subtypes. 24 Since subtypes 2a and 2c share the majority of their genoma, they are identified in different studies as 2a or 2ac, according to the genotyping method used.
Statistical analysis
The prevalence of each HCV genotype was calculated dividing the number of patients with that genotype by the number of patients analyzed. The relative risk (RR) of being infected by each HCV genotype, as compared to that of the control group, was calculated using the 2 Yates corrected test or the Fisher exact test whenever appropriate. All the reported P values are two tailed. Data analyses were performed with a SPSS/PC statistical package (SPSS, Chicago, IL, USA). Table 1 shows the prevalence of (and the RR of being infected by) HCV genotypes among patients with B cell NHL as compared to the control group.
Results
This last group was composed of patients previously referred to our laboratory from other Departments. When genotyping of these patients was performed we used the method of Cha et al 22 which allows the identification of four genotypes (1a,1b, 2 and 3), as previously mentioned. The lack of stocked serum prevented us from performing a second analysis with the method currently in use, which allows subtyping of genotypes. On the other hand, this last method could be applied to our patients with HCV RNA and B cell NHL, so that subtyping of these patients is available.
The distribution of genotypes in the control group was what was expected in our area, with the great proportion of patients (64.0%) being infected by genotype 1b, and the other genotypes each accounting for less than 10% of the cases. No dif- ferences were observed in the distribution of genotypes between healthy blood donors and patients with chronic liver disease. Among B cell NHL, genotype 1b was present in 45.1% of the cases, not significantly different from the control group. Genotypes 1a and 3 and mixed infections were never found, while an unclassified genotype was observed in only two patients (6.5%). On the contrary, a striking high prevalence (48.4%) of genotype 2ac was detected. Even assuming that all the patients of the control group infected by genotype 2 were in fact infected by genotype 2ac and not by genotype 2b, the RR of being infected by this subtype among B cell NHL was significantly higher than in the control group (5.37; P Ͻ 0.0001). Table 2 shows the main clinical, pathological and virological data of the 31 HCV RNA-positive patients. As previously described, 8, 11 the histotype most frequently associated with HCV infection was the lymphoplasmacytoid lymphoma/ immunocytoma, with a prevalence of 26% (18 out of 70) of HCV infection in this subgroup of patients.
The higher prevalence of genotype 2ac was also confirmed among immunocytomas (37.5%; RR 4.16; 95% confidence interval 1.94-8.94; P = 0019). Other histotypes frequently and significantly associated with HCV were the marginal zone and the follicle center lymphomas.
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No differences were observed in the distribution of NHL histotypes among patients with genotype 1b or 2ac, respectively, and no major differences were even observed among the two groups in the prevalence of a monoclonal component (71 vs 53%, P = 0.5348), cryoglobulins (64 vs 60%, P = 0.8845), membranoproliferative glomerulonephritis (7 vs 20%, P = 0.5977) and previous transfusions of blood products (21 vs 13%, P = 0.6513). On the contrary, more patients with genotype 1b (71 vs 33%) were affected by chronic hepatitis (P = 0.0930).
As far as response to treatment is concerned, overall, 10 patients were treated with IFN from 6 to 12 months. Among these, seven had genotype 1b: three of these patients did not respond to IFN and are currently alive with stable disease (Nos 9, 11 and 22 of Table 2 ); four progressed (Nos 7, 8, 13 and 19) and required further treatment, such as fludarabine, cyclophosphamide, corticosteroids, plasma exchange and even CHOP-like chemotherapy (CHT) (two of these later on died of disease progression). Among the three patients with genotype 2ac, one is alive with stable disease without requiring Table 2) have not yet been treated, while the remaining 11 patients were treated with different regimens of CHT (mainly fludarabine or CHOP-like regimens) and even with autologous stem cell transplantation (Nos 28 and 31).
Discussion
Phylogenetic analysis of specific regions of the HCV genoma showed clustering of nucleotide sequences into six major types, each with one to three subtypes. 23 There are clear differences in genotype prevalence among various geographic areas: type 1a, for instance, is prevalent in the United States; types 1b, 2a and 2b are more frequent in Japan and Taiwan; type 3 is the most common elsewhere in Asia, and type 4 in the Middle East. [25] [26] [27] [28] In Italy, type 1b is the most common, accounting for more than 60% of infected cases. [29] [30] [31] In our control population (healthy blood donors and patients with chronic liver disease, CLD), genotype 1b was present in 64% of cases, with each of the other genotypes being present in less than 10% of cases.
The clinicopathologic correlation of specific genoptypes is currently the subject of active investigation. Several reports suggest, in fact, a difference in pathogenicity and responsiveness to IFN treatment according to the genotype. In this setting, patients with genotype 1b have a more severe and progressive liver disease [12] [13] [14] [15] and are more likely to have a decreased likelihood of success with IFN therapy. [16] [17] [18] [19] On the contrary, genotype 2a is more likely to be found among apparently healthy blood donors than in patients with CLD, 32 or in patients with mild CLD or in those who respond better to IFN therapy. [12] [13] [14] [15] [16] [17] [18] [19] HCV might be a causative cofactor in the pathogenesis of B cell NHL: it is found in a significative percentage of some histotypes of NHL, 8, 11, 33, 34 it is known to be able to infect B lymphocytes circulating in the peripheral blood (PB) 35 or infiltrating the bone marrow (BM) 36 and the liver, 37 and in vitro studies have shown its ability to infect a human BM-derived B cell line and the PB MNC from healthy subjects. [38] [39] [40] If this is the case, it would appear appropriate to assess the prevalence of different HCV genotypes among the patients bearing a B cell NHL, with the aim of finding a possible correlation between a particular genotype and the lympho-proliferative disorder.
Among 31 B cell NHL patients who were genotyped in this study, we found a strikingly high prevalence of genotype 2ac (48.4%), with the relative risk of infection for this genotype being 5.37, highly significant (P Ͻ 0.0001).
As far as correlation between genotype and clinical characteristics, no major differences were observed in the distribution of NHL histotypes, and in the prevalence of a monoclonal component, cryoglobulins, membranoproliferative glomerulonephritis and transfusions of blood products, while more patients with genotype 1b (71 vs 33%) were affected by chronic hepatitis. This confirms the findings of Zignego et al, 30 who observed a higher prevalence of genotype 2a among cryoglobulinemic patients without symptomatic liver disease than among those with chronic hepatitis.
As far as response to therapy is concerned, it must be pointed out that up to now no specific protocol was available at our Institution for the treatment of HCV-related lymphomas. Due to the heterogeneity of treatments employed, it appears to be difficult to draw any conclusion on the relationship between genotype and response to therapy in our patients. None the less, it can be underlined that among the patients who received IFN 4/7 patients with genotype 1b progressed regardless of IFN treatment and the other three did not improve. On the contrary, of the three patients with genotype 2ac, one is in stable condition without any further treatment, one has recovered from renal impairment and is currently in stable condition and the last one is in complete remission without any evidence of lymphoma and HCV RNA negative.
Regression of the BM lymphomatous infiltration seen in this last patient was recently also documented in a small number of cases with mixed cryoglobulinemia and NHL which, under IFN treatment, cleared the virus. Interestingly, in that study genotype 1b was closely associated with the lack of response to antiviral therapy, with none of the patients with this genotype showing clearance of the virus or disappearance of the lymphomatous infiltrate. 41 These observations suggest that active viral replication is needed to support the B cell monoclonal proliferation and that with IFN treatment, through its antiproliferative effect and its viral antireplicative activity, a regression of the lymphoma can be obtained: these results seem to be closely correlated with the viral genotype. Even taking into account the low number of patients reported, the possible therapeutic benefit of IFN in this setting of patients should be regarded as promising.
Few papers available in the literature report data on HCV genotype among lymphoproliferative disorders. Apart from Mazzaro et al, 34 who reported a higher prevalence of genotype 1b (70.2%), among the other 138 patients reported 57 (41.3%) were bearing genotype 2a/2ac and 56 (40.5%) genotype 1b, confirming our findings. In particular, this was observed among patients with B cell NHL complicating MC, 6 among patients with MC, 30 a lymphoproliferative disorder which is currently considered an expression of low-grade B cell NHL, 8 among patients with monoclonal gammopathies, 31, 42 and among patients with B cell NHL complicating MC or arising 'de novo' (Refs 43, 44 and the present report). Moreover, genotype 2a was recently found in a high percentage of Italian patients with autoimmune hepatitis. 45 All these data taken together suggest that genotype 2ac might be involved in the pathogenesis of lymphoproliferative and autoimmune disorders.
Differences in viral genotype can be important in defining epidemiology, the natural history and widespread nature of the disease. For instance, differences in susceptibility to the host immune response, in replicative or mutation rates, or in viral proteins, might lead to different clinical expression of the HCV-related disease, ranging from apparent benign infection to different degrees of liver damage, from MC with or without chronic hepatitis and/or renal involvement, to B cell NHL.
Probably different genetic, environmental and viral factors are involved in the pathogenesis of different disorders and the viral genotype represents only one piece of a complex interaction between host and virus. None the less, the observations reported here deserve further investigation on a larger number of patients. It is probably time to include viral genotype in the initial workup of patients with HCV infection. This might contribute to the prognostic profile and to the management of HCV-infected patients.
